Biotech Values

[zipjet]

IMO—I doubt that many MS patients will even know about the new Copaxone option unless they are made aware of it by their neuro.

I think the neuro's will tell their patients unless they think compliance would suffer - which I think it would. It is easier to get in the habit of doing something every day.

IF there is no change in the NCE, why couldn't the generic provider get approval for the new thrice weekly dose?

ij